BriaCell 2024 SABCS Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
BriaCell Provides Update to Its Board of Directors
BriaCell Therapeutics Shares Are Trading Higher After the Company Announced It Dosed the First Patient in Its Phase 1/2 Study of Bria-OTS.
Briacell Therapeutics Has Dosed The First Patient In Its Phase 1/2 Study To Evaluate The Safety And Efficacy Of Bria-OTS, Briacell's Personalized Next Generation Immunotherapy
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
10-K: FY2024 Annual Report